INNOVIVA, INC. Operating Lease, Weighted Average Discount Rate, Percent
INNOVIVA, INC. (INVA) had Operating Lease, Weighted Average Discount Rate, Percent of 5.30% as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-05
- 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 5.30%.
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 5.30%.
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 5.30%.
- 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 6.90%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2026-06-30 | 5.30% 10-Q · filed 2026-08-05 |
| 2026-03-31 | 5.30% 10-Q · filed 2026-05-06 |
| 2025-12-31 | 5.30% 10-K · filed 2026-02-25 |
| 2025-09-30 | 6.90% 10-Q · filed 2025-11-05 |
| 2025-06-30 | 7.00% 10-Q · filed 2025-08-06 |
| 2025-03-31 | 6.90% 10-Q · filed 2025-05-07 |
| 2024-12-31 | 7.00% 10-K · filed 2025-02-26 |
| 2024-09-30 | 7.20% 10-Q · filed 2024-11-06 |
| 2024-06-30 | 7.20% 10-Q · filed 2024-07-31 |
| 2024-03-31 | 7.50% 10-Q · filed 2024-05-08 |
| 2023-09-30 | 7.50% 10-Q · filed 2023-11-01 |
| 2023-06-30 | 8.40% 10-Q · filed 2023-08-02 |
| 2023-03-31 | 7.60% 10-Q · filed 2023-05-09 |
| 2022-09-30 | 7.50% 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |